17 documents

Read All
20:15 , Apr 30, 2019 |  BC Innovations  |  Distillery Therapeutics

BMP2/BMP6/activin A-based chimera for bone repair

DISEASE CATEGORY: Musculoskeletal INDICATION: Bone repair Cell culture and non-human primate studies identified chimera composed of BMP2, BMP6 and activin A sequences that could help repair bone.The chimera consists of human BMP2 engineered with substitutions...
Read More
21:43 , Aug 11, 2017 |  BC Extra  |  Company News

Management tracks: Orchard, Maverick, Pieris

Gene therapy company Orchard Therapeutics Ltd. (London, U.K.) named Mark Rothera president and CEO. He was chief commercial officer at PTC Therapeutics Inc. (NASDAQ:PTCT). T cell therapy company Maverick Therapeutics Inc. (Brisbane, Calif.) named James...
Read More
21:15 , May 2, 2017 |  BC Extra  |  Company News

Management tracks

The Association of the British Pharmaceutical Industry named Lisa Anson president. She is president of the U.K. and Ireland division at AstraZeneca plc (LSE:AZN; NYSE:AZN). Effective June 30, President and CEO C. Randal Mills is...
Read More
01:40 , Dec 30, 2016 |  BC Week In Review  |  Company News

Bioventus, Galderma deal

Galderma granted Bioventus U.S. rights to commercialize Durolane for pain associated with knee osteoarthritis. Bioventus said it plans to submit a PMA to FDA this quarter for the transparent gel containing stabilized hyaluronic acid (HA)....
Read More
07:00 , Aug 15, 2016 |  BC Week In Review  |  Company News

Bioventus sales and marketing update

Bioventus launched GELSYN-3 in the U.S. to treat pain associated with osteoarthritis of the knee. The wholesale acquisition cost (WAC) is $345 per 2 mL injection; one treatment comprises three injections of hyaluronic acid. Bioventus...
Read More
07:00 , Aug 8, 2016 |  BC Week In Review  |  Financial News

Bioventus withdraws IPO

Bioventus Inc. , Durham, N.C.   Business: Musculoskeletal, Neurology   Date announced: 2016-08-02   Type: IPO   Underwriters: JPMorgan; Piper Jaffray; Stifel, Nicolaus; Leerink Partners   Note: Bioventus withdrew its IPO.  ...
Read More
07:00 , Jul 25, 2016 |  BC Week In Review  |  Financial News

Bioventus amends IPO

Bioventus Inc. , Durham, N.C.   Business: Musculoskeletal, Neurology   Date announced: 2016-07-19   Type: IPO   To be raised: Up to $158.8 million   Shares: 8.8 million   Price: $16-$18   Underwriters: JPMorgan; Piper...
Read More
07:00 , Jul 11, 2016 |  BC Week In Review  |  Financial News

Bioventus proposes IPO

Bioventus Inc. , Durham, N.C.   Business: Musculoskeletal, Neurology   Date announced: 2016-06-30   Type: IPO   To be raised: Up to $150 million   Shares: TBD   Price: TBD   Underwriters: JPMorgan; Piper Jaffray;...
Read More
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Ground up

Steve Edelson, Senior Editor   As the third quarter gets under way, biotech is shaking off the hangover of the Brexit vote while facing the overhang of the November election in the U.S. Fifteen bankers...
Read More
07:00 , Oct 26, 2015 |  BC Week In Review  |  Company News

Bioventus sales and marketing update

Bioventus launched Supartz FX sodium hyaluronate in the U.S. to treat pain in patients with knee osteoarthritis (OA). The injectable 1% avian-derived sodium hyaluronate is given once weekly for three to five weeks. The wholesale...
Read More